We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

19 hedge funds and large institutions have $25M invested in Galmed Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

118% more capital invested

Capital invested by funds: $11.4M → $25M (+$13.5M)

73% more funds holding

Funds holding: 11 → 19 (+8)

0.06% more ownership

Funds ownership: 0.06% → 0.12% (+0.06%)

Holders
19
Holders Change
+8
Holders Change %
+72.73%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
4
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$3.28M
2
SFM
Sphera Funds Management
Israel
+$1.95M
3
6CM
683 Capital Management
New York
+$820K
4
JGC
J. Goldman & Co
New York
+$511K
5
Morgan Stanley
Morgan Stanley
New York
+$377K

Top Sellers

Rank Fund Capital Flow
1
GL
GLG LLC
New York
-$1.36M
2
SKK
Shepherd Kaplan Krochuk
Massachusetts
-$167K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$57K
Name Holding Trade Value Shares
Change 		Change in
Stake
6CM
1
683 Capital Management
New York
$5.94M +$820K +555 +18%
MIH
2
Meitav Investment House
Israel
$4.36M +$3.91M +2,646 New
NCM
3
Nantahala Capital Management
Connecticut
$3.66M +$3.28M +2,222 New
PWAM
4
Park West Asset Management
California
$2.68M +$102K +69 +4%
SFM
5
Sphera Funds Management
Israel
$2.16M +$1.95M +1,323 New
II
6
Ibex Investors
Colorado
$2.08M +$1.86M +1,261 New
Morgan Stanley
7
Morgan Stanley
New York
$1.53M +$377K +255 +38%
PAWC
8
P.A.W. Capital
Connecticut
$961K – – –
JGC
9
J. Goldman & Co
New York
$569K +$511K +346 New
Renaissance Technologies
10
Renaissance Technologies
New York
$345K +$309K +209 New
Deutsche Bank
11
Deutsche Bank
Germany
$246K +$222K +150 New
EMG
12
ETF Managers Group
New Jersey
$119K +$103K +70 New
CA
13
CapWealth Advisors
Tennessee
$109K – – –
LNWWM
14
Laird Norton Wetherby Wealth Management
California
$92K – – –
AAMU
15
Amundi Asset Management US
Massachusetts
$57K +$50.2K +34 New
JP Morgan Chase
16
JP Morgan Chase
New York
$36K +$28.1K +19 +633%
Macquarie Group
17
Macquarie Group
Australia
$8K +$7.39K +5 New
UBS Group
18
UBS Group
Switzerland
$7K +$5.91K +4 New
RFA
19
Reilly Financial Advisors
California
$2K – – –
GL
20
GLG LLC
New York
– -$1.36M -836 Closed
SKK
21
Shepherd Kaplan Krochuk
Massachusetts
– -$167K -102 Closed
Acadian Asset Management
22
Acadian Asset Management
Massachusetts
– -$57K -35 Closed

GLMD Hedge Fund Activity: Q4 2017 in Review

19 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2017, worth a combined $25M — up 118% from $11.4M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new GLMD positions and 3 closed out — a net gain of 8 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.28M. The largest seller was GLG LLC, exiting entirely with an estimated $1.36M sold.

  • 19 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2017, up from 11 in Q3 2017.
  • Funds reported $25M of Galmed Pharmaceuticals stock for Q4 2017, up 118% quarter-over-quarter.
  • 11 funds opened new Galmed Pharmaceuticals positions in Q4 2017 and 3 closed out, a net change of +8 holders.
  • The largest Galmed Pharmaceuticals buyer in Q4 2017 was Nantahala Capital Management, an estimated $3.28M added.
  • The largest Galmed Pharmaceuticals seller in Q4 2017 was GLG LLC, an estimated $1.36M sold.

Based on aggregated 13F filings for Q4 2017.